Connext Successfully Administers First Dose of CNT201 for Dupuytren's Contracture
- Written by PR Newswire Asia - Asian Spectator
World's First Genetically Recombinant Collagenase Therapeutics (CNT201) Begins Clinical Trials in Australia
SEOUL, South Korea, July 30, 2024 /PRNewswire/ -- Connext has announced the successful first administration of CNT201, its therapeutic treatment for Dupuytren's contracture, in patients.
Dupuytren's contracture is a debilitating condition...